Biosig Tech | 10-Q: FY2025 Q2 Revenue: USD 0
I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2025 Q2, the actual value is USD 0.
EPS: As of FY2025 Q2, the actual value is USD -0.74.
EBIT: As of FY2025 Q2, the actual value is USD -20.37 K.
Segment Revenue
- Revenue for the three months ended June 30, 2025, was $0, compared to $13 for the same period in 2024. For the six months ended June 30, 2025, revenue was $0, compared to $27 in 2024.
Operational Metrics
- Net Loss: For the three months ended June 30, 2025, the net loss was -$20,368, compared to -$3,911 for the same period in 2024. For the six months ended June 30, 2025, the net loss was -$23,169, compared to -$7,326 in 2024.
- Operating Expenses: Total operating expenses for the three months ended June 30, 2025, were $20,365, compared to $5,305 for the same period in 2024. For the six months ended June 30, 2025, operating expenses were $23,350, compared to $8,756 in 2024.
- General and Administrative Expenses: For the three months ended June 30, 2025, these expenses were $19,792, an increase from $4,914 in 2024. For the six months ended June 30, 2025, expenses were $22,748, up from $7,796 in 2024.
Cash Flow
- Operating Cash Flow: Net cash used in operating activities for the six months ended June 30, 2025, was -$2,393, compared to -$2,795 in 2024.
- Investing Cash Flow: Net cash provided by investing activities was $366 for the six months ended June 30, 2025.
- Financing Cash Flow: Net cash provided by financing activities was $4,700 for the six months ended June 30, 2025.
Unique Metrics
- Stock-Based Compensation: For the three months ended June 30, 2025, stock-based compensation was $12.1 million, compared to $4.3 million in 2024. For the six months ended June 30, 2025, it was $14.2 million, compared to $5.4 million in 2024.
Future Outlook and Strategy
- Core Business Focus: The company is focusing on the commercialization of the PURE EP™ Platform and the development of new product candidates. It is also working on the integration and scaling of Streamex’s tokenization platform and digital asset infrastructure.
- Non-Core Business: The company is developing real-world asset (RWA) tokenization solutions, including commodities-on-chain initiatives, through its acquisition of Streamex.
- Priority: The company is actively exploring various funding sources, including public or private equity offerings, strategic partnerships, and government grants, to support its operations and strategic initiatives.
